Pfizer Reports Five-Year PALOMA-2 Data for Ibrance in HR-Positive Breast Cancer

Pfizer today presented five-year follow-up data from the Phase 3 PALOMA-2 trial evaluating Ibrance (palbociclib) plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. The data showed that the progression-free survival benefit of Ibrance was maintained over five years of follow-up.